<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18492">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134210</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-0214-04</org_study_id>
    <nct_id>NCT02134210</nct_id>
  </id_info>
  <brief_title>Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO
      who have not yet received any biologic therapy for any indication (other than insulin or
      hormones).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center
      global study. The primary end point is 75% improvement from baseline according to the
      Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and
      safety at a dosage of 50mg subcutaneous (Sc) twice weekly.

      Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center
      global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PASI-75</measure>
    <time_frame>12-weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enbrel 50mg twice weekly times 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHS-0214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHS-0214 50mg twice weekly times 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Head-to-head comparison</description>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
    <other_name>Enbrel</other_name>
    <other_name>European Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHS-0214</intervention_name>
    <arm_group_label>CHS-0214</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults

          -  PsO diagnosis for 6 months

          -  Active disease: PASI greater than or equal to 12, Physician's Static Global
             Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),

          -  Body Surface Area (BSA) involved with PsO greater than or equal to 10%

          -  Dermatology Life Quality Index (DQLI) greater than or equal to 10

          -  Previously received phototherapy or systemic non-biologic therapy for PsO

        Exclusion Criteria:

          -  Forms of Psoriasis other than PsO

          -  Drug induced Psoriasis

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Presence of significant comorbid conditions

          -  Chemistry and hematology values outside protocol specified range

          -  Major systemic infections
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara K Finck, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Coherus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Dermatology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Leonardi, M.D.</last_name>
      <phone>314-721-5565</phone>
    </contact>
    <investigator>
      <last_name>Craig Loenardi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>May 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PsO</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
